Description
The study shows that Abi3-Gngt2 deletion reduces amyloid deposition but exacerbates tau pathology, both linked to inflammatory gliosis. The mechanistic basis for this divergent effect on the two cardinal AD pathologies is not explained, yet understanding this could inform therapeutic targeting of neuroinflammation.
Gap type: unexplained_observation Source paper: Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways. (2022, Alzheimer’s research & therapy, PMID:35897046)
Resolution criteria
Resolution requires: (1) Cell-type specific transcriptomics (microglia, astrocytes, oligodendrocyte progenitors) from AD mouse models with combined amyloid and tau pathology, identifying >=5 genes with opposite expression patterns in amyloid vs tau environments; (2) Gain/loss-of-function experiments in iPSC neurons or dual-pathology mouse models for >=2 identified pathways, showing that modulating the pathway differentially affects amyloid vs tau burden; (3) Mechanistic link: receptor-ligand pairs or secreted factors from glia that directly engage amyloid clearance machinery vs tau aggregation machinery. Inflammatory marker measurement without pathway dissection is insufficient.